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Abstract  
To study the effect of formulas on the estimation of dietary sodium intake (sodium intake) and its association with mortality, we analysed the Trials of Hypertension Prevention follow-up data. Sodium intake was assessed by measured 24-h urinary sodium excretion and estimations from sodium concentration using the Kawasaki, Tanaka and INTERSALT formulas. We used both the average of 3-7 urinary measurements during the trial period and the first measurement at the beginning of each trial. Additionally, we kept sodium concentration constant to test whether the formulas were independently associated with mortality. We included 2,974 individuals aged 30-54 years with prehypertension, not assigned to sodium intervention. During a median 24-year follow-up, 272 deaths occurred. The average measured sodium intake was 3,766±1,290mg/d. All estimated values, including those with constant sodium concentration, were systematically biased with over-estimation at lower levels and under-estimation at higher levels. There was a significant linear association between the average measured sodium intake (i.e. gold standard method) and mortality. This relationship was altered by using the estimated sodium intakes. There appeared to be a J- or U-shaped relationship for the average estimated sodium by all formulas. Despite variations in the sodium-mortality relationship among various formulas, a common pattern was that all estimated values including those with constant sodium, appeared to be inversely related to mortality at lower levels of sodium intake. These results demonstrate that inaccurate estimates of sodium cannot be used in association studies, particularly as the formulas per se seem to be related to mortality independent of sodium.
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There is a causal, linear relationship between sodium intake and blood pressure, ADDIN EN.CITE 1-4 and a continuous relationship between blood pressure and cardiovascular disease (CVD) mortality. ADDIN EN.CITE 5, 6 Several lines of evidence have shown that a lower sodium intake is associated with a reduced risk of CVD events and mortality. ADDIN EN.CITE 7-10  However, a few recent cohort studies have reported a J-shaped relationship, i.e. both lower and higher sodium intake were associated with an increased risk. ADDIN EN.CITE 11-13  These studies have several methodological problems, one of which is the biased estimate of individuals’ usual sodium intake from spot urine using a formula. ADDIN EN.CITE 14-17 An analysis of the Trials of Hypertension Prevention (TOHP) follow-up data demonstrated that use of an estimated sodium intake based on urinary sodium concentration by the Kawasaki formula changed the direct linear relationship between sodium intake and mortality seen when sodium was measured by the gold standard multiple non-consecutive 24-hour urine collections. ADDIN EN.CITE 7, 8, 18  
A number of other formulas, e.g. Tanaka, ADDIN EN.CITE 19 INTERSALT, ADDIN EN.CITE 20 have also been used to estimate sodium intake from spot urine. All these formulas include age, weight, height and urinary creatinine concentration, though the equations vary across formulas. For example, some formulas have sex-specific equations ADDIN EN.CITE 20, 21 and others also include urinary potassium concentration. ADDIN EN.CITE 20 These variables are associated with sodium intake and also strongly related to death, and therefore may confound the relationship between the estimated sodium intake and mortality. To investigate the impact of the formulas on the estimation of sodium intake and its association with mortality, we performed a secondary analysis of the TOHP follow-up data. 
Methods
Anonymized data and materials from the TOHP trial periods have been made publicly available at https://biolincc.nhlbi.nih.gov/studies/tohp/ and researchers can apply to use the trial data. The methods of the original TOHP and the subsequent follow-up study for mortality have been reported in detail elsewhere. ADDIN EN.CITE 8, 22-24 The number of participants included/excluded was the same as that in our previous analysis. ADDIN EN.CITE 18 In brief, our current study included 1,844 individuals with high-normal BP in TOHP I23 and 1,167 individuals with prehypertension and a body mass index of 110% to 165% of desirable body weight in TOHP II.24 Among these participants, 37 took part in both phases, and therefore 2,974 unique individuals (age 30-54 year at baseline) were included. We excluded individuals who were randomized to sodium reduction group during the trial period. Three to seven 24h urine collections were made during the trials which lasted for 18 months for TOHP I and 3-4 years for TOHP II. 
The trial period constitutes the baseline exposure period for subsequent follow-up. Post-trial follow-up was conducted for mortality after each trial had been completed. A search of the National Death Index was carried out, accruing death information through December 2013. 
The primary outcome in this analysis is all-cause mortality in relation to sodium intake estimated by various methods. We also examine the accuracy of the different estimates of sodium intake both at population and individual level.
Sodium intake was assessed by two methods: (1) measured by 24-h urinary sodium excretion and (2) estimated from sodium concentration using formulas. For each method, we estimated the values based on both the average of 3 to 7 urinary measurements during the trial period and the first urinary measurement at the beginning of each trial. The average measured sodium intake is the best characterized measure of individuals’ usual sodium intake and therefore considered as the gold standard method. 
We used three formulas, i.e. Kawasaki,21 Tanaka ADDIN EN.CITE 19 and INTERSALT, ADDIN EN.CITE 20 all of which have been commonly used for estimating sodium intake from spot urine.  The calculations of sodium intake, i.e. 24-h urinary sodium (UNa), are described below.
Kawasaki formula21 
24h UNa (mg) = 23 × (16.3 × XNa0.5) 
where XNa = [spot Na (mmol/L)/spot Cr (mg/dL) × 10] × [Pr24hCr (mg/d)].
Pr24hCr (mg/d) for men = [−12.63 × age (y)] + [15.12 × weight (kg)] + [7.39 × height (cm)] - 79.9. 
Pr24hCr (mg/d) for women = [−4.72 × age (y)] + [8.58 × weight (kg)] + [5.09 × height (cm)] − 74.5.

Tanaka formula ADDIN EN.CITE 19
24h UNa (mg) = 23 × (21.98 × XNa0.392), where XNa = [spot Na (mmol/L)/spot creatinine (mg/dL) × 10] × [Pr24hCr (mg/d)].
Pr24hCr (mg/d) = [−2.04 × age (y)] + [14.89 × weight (kg)] + [16.14 × height (cm)] − 2244.45.

INTERSALT formula ADDIN EN.CITE 20 
Male: 24h UNa (mg) = 23 × {25.46 + [0.46 × spot Na (mmol/L)] – [2.75 × spot Cr (mmol/L)] − [0.13 × spot K (mmol/L)] + [4.10 × BMI (kg/m2)] + [0.26 × age (y)]} 
Female:  24h UNa (mg) = 23 × {5.07 + [0.34 × spot Na (mmol/L)] − [2.16 × spot Cr (mmol/L)] − [0.09 × spot K (mmol/L)] + [2.39 × BMI (kg/m2)] + [2.35 × age (y)] – [0.03 × age2 (y)]}

Spot urine was not collected in TOHP. We used 24-h urinary sodium concentration instead of spot urinary sodium concentration in the above formulas, i.e. “spot UNa”, “spot Cr” and “spot K” refer to sodium, creatinine and potassium concentration of 24-h urine, respectively. 
In additional analyses, we used a constant sodium concentration in the formulas, to test whether the formulas per se were associated with mortality independent of sodium. The constant for men and women was the mean urinary sodium concentration of their respective group. 
Statistical analysis
Mean bias was calculated as the difference between the estimated 24-h urinary sodium excretion and the measured value. Paired t-tests were carried out to test whether the mean bias was statistically significant. Bland-Altman plots were used to compare agreement of the estimated sodium intakes with the measured values. To examine whether the trend of the bias was statistically significant and to quantify the magnitude of the bias in relation to sodium level, we calculated the predicted differences (i.e. bias) from the regression of the differences between the estimated and the measured sodium over their average, and then performed the regression of the absolute value of residuals from this model on the average of the estimated and the measured sodium.25 
In addition to the analyses with sodium concentration kept constant in the formulas, we performed further analyses to examine whether other variables in the formulas were influencing the association of estimated sodium intake with mortality. We calculated the predicted sodium concentration from regression on average sodium concentration of the 3-7 24-h urine collections during the trial period with age, sex, height and body weight at baseline as covariates. We then used the predicted sodium concentration to estimate sodium intake with the formulas. The results were the same as those when sodium concentration was kept constant (data not shown).
The measured sodium intake was grouped into categories of <2,300, 2,300 to <3,600, 3,600 to <4,800, and ≥4,800 mg/d, where 2,300 mg/d represents the currently recommended upper level for adults in the USA,26 and 3,600 mg/d represents the median sodium intake in the US population aged 31 to 50 years.27 For the estimated sodium intake, due to over-estimation or under-estimation by different formulas, they were grouped into categories of <3,600, 3,600 to <4,800, 4,800 to <6,000, and ≥6,000 mg/d for the Kawasaki formula, and <3,600, 3,600 to <4,800, and ≥4,800 mg/d for the Tanaka and INTERSALT formulas. 
Baseline characteristics were reported as percentages or means and were tested for trend over sodium categories using chi-square statistics or regression analysis. Cox regression analysis was performed to examine the association between sodium intake and mortality. Separate analyses were carried out for sodium intake as a continuous variable and in categories. The Cox regression models were stratified by study phase and all models were adjusted for clinic, age, sex, race/ethnicity, other treatment assignments, education, baseline weight, alcohol use and amount, smoking, exercise, and family history of CVD. Penalized splines with 4 degrees of freedom were fit to examine linearity of effect in models adjusting for the same factors. Both these and the Bland-Altman plots were fit using R. All other analyses were conducted using SAS version 9.3 (SAS, Cary, NC).
Results
Among the 2,974 participants included in the analysis, 68% were men, 16% were African American, and the mean age at baseline was 43 years. The mean number of 24-h urine collections during the trial periods, was 4.4 in TOHP I and 3.5 in TOHP II. 
Bias of the estimated sodium intake 
The means and distributions of sodium intake (i.e. 24-h urinary sodium excretion) estimated by various methods are shown in Supplement Figure S1. Compared with the measured 24-h urinary sodium, all estimated values (both the average and the first estimates) had smaller variance. The overall mean (±SD) measured 24-h urinary sodium from 3-7 24-h urine collections (i.e. gold standard) during the trial periods was 3,766±1,290 mg/d (9.42±3.23 g/d salt). Compared with the average measured 24-h urinary sodium, the mean bias for the average estimated sodium (i.e. difference between the average estimated and the average measured sodium) ranged from -78 mg/d (95% CI: -113 to -42) to 1,299 mg/d (1,269 to 1,329), with the INTERSALT formula being the least biased and the Kawasaki formula being the most biased. The mean bias for the first estimated sodium (i.e. difference between the first estimated and the average measured sodium) was -74 mg/d (95%CI: -112to -36), 75 mg/d (34 to 115), and 1,264 mg/d (95%CI: 1,223 to 1,304) for the INTERSALT, Tanaka and Kawasaki formula, respectively (Supplement Table S1). 
The mean first measured 24-h urinary sodium was 3,941±1,812 mg (9.85±4.53 g/d salt). In comparison with the average measured value, the first measured 24-h urinary sodium over-estimated the intake by 159 mg/d (95%CI: 109 to 210) and had a wider variability.
Comparing the first estimated 24-h urinary sodium excretions with the first measured ones, the mean bias was -95 mg/d (95% CI: -149 to -41), -240 mg/d (95% CI: -295 to -185) and 1,088 mg/d (95% CI: 1042 to 1134) with the Tanaka, INTERSALT and Kawasaki formula respectively (Supplement Table S1). 
The Bland-Altman plots showed poor agreement between the measured and the estimated 24-h urinary sodium by all formulas for both the average and the first estimated values (Figure 1). Compared with the average measured (gold standard), all estimates were systematically biased with over-estimation at lower levels and under-estimation at higher levels (Figure 1). The limits of agreement were wider for the first estimated sodium by the Kawasaki formula (Figure 1). For the comparison between the first estimated and the first measured 24-h urinary sodium, there was a similar pattern for all formulas (Figure 1).      
When sodium concentration was kept constant, the estimated 24-h urinary sodium showed a similar systematic bias, i.e. over-estimation at lower levels and under-estimation at higher levels, for all formulas and for both the average (i.e. average estimated vs average measured sodium) and the first estimates (i.e. first estimated vs first measured sodium) (Supplement Figure S2). For the Kawasaki formulas, limits of agreement were wider, and the variability of the bias increased with increasing sodium level (Supplement Figure S2). 
The regression analyses in which the slopes indicate the changes in bias for a 1 mg/d increase in the average of estimated and measured 24-h urinary sodium, showed that the trend of the bias was significant for all estimates by all formulas (Figure 1 and Supplement Figure S2). The slope was less extreme for the Kawasaki formula compared with all others.
Association with mortality
Baseline characteristics by categories of the average measured 24-h urinary sodium are shown in Supplement Table S2.  During the post-trial follow-up, 272 deaths occurred, 189 among TOHP I participants and 83 among TOHP II participants (Table 1). Median follow-up time was 23.9 years for TOHP I and 18.8 years for TOHP II.
Figure 2 shows the spline plots of different average estimates of sodium intake and mortality. The average measured sodium appeared to show a positive linear association with mortality within the range of 1,200 to 9,000 mg/d (3.00 to 22.50 g/d salt) (Figure 2a). Compared with sodium intake of 3,600 to <4,800 mg/d (9.00 to 12.00 g/d salt), the hazard ratios for sodium levels of 2,300 to <3,600 (5.75-9.00 g/d salt) and <2,300 mg/d (5.75 g/d salt) were 0.94 and 0.73 respectively, but the trend across categories did not reach statistical significance (Table 1). When sodium was entered as a continuous variable, a 1,000 mg/d higher sodium level was associated with a 12% increase in mortality (P=0.032) (Table 1).
For the average estimated sodium intakes by the formulas, due to the over-estimation at lower levels and under-estimation at higher levels, their distributions were shifted towards the mean values as shown by the rug marks on X axis of the spline plots (Figure 2b-d).  There appeared to be a J- or U-shaped relationship between the average estimated sodium intake and mortality for all formulas, although the test for deviation from linearity was not significant. Instead, the trend analysis was statistically significant for linearity for the Kawasaki and Tanaka formula, but the sample size was small at tails as shown by the wide 95% CIs (Figure 2 and Table 2). 
When sodium concentration was kept constant, the average estimated sodium intakes by the Kawasaki and Tanaka formulas appeared to be inversely associated with mortality at a level of less than 4,000 mg/d (10 g/d salt) (Figure 3) and significantly so for the Kawasaki formula (Table 2). For sodium level of ≥4,000 mg/d, the spline was flat. For the INTERSALT formula, the average estimated sodium with constant sodium concentration showed a U-shaped association with mortality (Figure 3).  
The first measured 24-h urinary sodium showed no association with mortality, likely due to the lack of precision in the measurement (Supplement Figure S3a). For the first estimated sodium, at lower levels the spline plots were either flat or slightly flip up, and at higher sodium levels, a higher sodium appeared to be associated with an increased risk, particularly for the Kawasaki and Tanaka formula (Supplement Figures S3b and S3d). Statistical tests were not significant for either linear or non-linear splines. When sodium concentration was kept constant, the first estimated values appeared to show an inverse association, i.e. a lower sodium intake being associated with an increased risk, at lower sodium levels (Figure 3). At higher sodium levels, the lines were either flat (INTERSALT) or inversely related to mortality (Kawasaki and Tanaka). Tests were not significant for either linear or nonlinear relationship. 
Discussion
Our analysis showed that 24-h urinary sodium excretions estimated from sodium concentration using the three commonly used formulas (Kawasaki, Tanaka and INTERSALT) all are systematically biased with over-estimation at lower levels and under-estimation at higher levels of sodium intake. Furthermore, when sodium concentration was kept constant, the estimated values showed a similar systematic bias for all formulas. These results suggest that other variables in the formulas, independent of sodium, are contributing to the biased estimates. This is further evident by the findings that all estimated 24-h urinary sodium excretions altered the linear relationship with mortality observed in the TOHP follow-up study. A common pattern of the alterations by all formulas including those with a constant sodium concentration is that, at lower levels of sodium intake, all estimated 24-h urinary sodium excretions appeared to be inversely related to mortality. Taken together, our results suggest that variables used in the formulas, other than sodium, could at least partially explain the increased risk of mortality with a lower sodium intake reported in some cohort studies. This is not surprising, given that other variables in the formulas (e.g. age, sex, body weight and creatinine concentration) are known to be associated with mortality. ADDIN EN.CITE 28, 29 
Over the past 30 years, numerous formulas have been developed among various populations in an attempt to estimate population sodium intake from spot urine due to the obvious advantage of collecting spot urine over 24-h urine in terms of burden to the participants, costs, and challenges in implementation. However, these formulas have been inappropriately used to estimate an individual’s usual sodium intake and its association with health outcome. ADDIN EN.CITE 11-13 The most commonly used formulas are Kawasaki, Tanaka and INTERSALT. Our findings of a similar systematic bias by all these three formulas are in agreement with a number of studies from various countries including the UK, ADDIN EN.CITE 14 USA, ADDIN EN.CITE 17 Portugal,15 New Zealand,30 Italy, ADDIN EN.CITE 14 India ADDIN EN.CITE 31 and China. ADDIN EN.CITE 32, 33 
Our study also showed that, at the population level, there was a significant bias in estimating mean sodium intake. The magnitude and direction of the mean bias varied between formulas and the Kawasaki was the most biased, over-estimating mean sodium intake by 1,299 mg/d (3.2 g/d salt). The population level bias found in our study is also in keeping with several other studies, ADDIN EN.CITE 15, 31 but in contrast with the study by Mente et al. who reported that the Kawasaki formula produced the least bias at the group level compared with Tanaka and INTERSALT in a validation study involving 540 participants from 11 countries. ADDIN EN.CITE 34 The discrepancy between study findings could be attributable to various factors, e.g. difference in the timing of spot urine collection, study population and the levels of their sodium intake, as well as quality of the studies, particularly the inclusion of a large proportion of incomplete 24-h urine samples (≈70%) in Mente’s study. ADDIN EN.CITE 35, 36  Both the Kawasaki and Tanaka formulas were developed in a Japanese population with a high sodium intake, and the Kawasaki formula used 2nd morning fasting urine samples. ADDIN EN.CITE 19, 21 However, using an identical protocol as that for the development of the Kawasaki formula, a study in a Chinese population who also had a high sodium intake showed that the Kawasaki formula was unreliable, under-estimating mean population sodium intake by 740 mg/d (1.9 g/d salt).32
An accurate measurement of an individual’s sodium intake is vital for epidemiological studies relating sodium intake to health outcome.37 24-h urinary sodium excretion is considered the gold standard method for assessing sodium intake. Despite this, one single 24-h urine cannot be used to estimate an individual’s usual intake due to the large day-to-day variations in sodium intake. To get a reasonably reliable estimate for an individual, a minimum of three 24-h urine collections are needed. ADDIN EN.CITE 38-40  TOHP collected 3 to 7 24-h urines over a period of 18 months to 4 years, and demonstrated a direct linear relationship between sodium intake and mortality. However, replacing the accurately measured sodium intake with those estimated from sodium concentration using the formulas changed this linear relationship. The average estimated sodium intakes appeared to show a J- or U-shaped relationship with mortality for all three formulas. These findings indicate that the biased estimation of sodium intake from spot urine by the formulas could explain much of the paradoxical J-shaped association reported in some of the cohort studies. ADDIN EN.CITE 12
By using a constant sodium concentration, our analysis further confirmed that other variables in the formulas (e.g. age, sex, body weight, creatinine concentration) independently biased the estimations of sodium intake and altered the linear association between sodium intake and mortality. It is well known that age is the major risk factor for chronic diseases and mortality. There is also a variation in sodium intake between different age groups and a reduction in sodium intake has a greater effect on BP in the elderly compared with young people.1 Both sodium intake and mortality rates are higher in men compared with women.41 A higher body weight (overweight/obesity) increases the risk of type II diabetes and death.28 In obese individuals, BP are more sensitive to the changes in sodium intake.42 24-h urinary creatinine excretion is a marker of muscle mass - an indicator of fitness which is also associated with sodium intake and mortality. ADDIN EN.CITE 29 Therefore, the use of creatinine concentration in the formulas may further confound the estimated sodium intake, as well as the associated risk. 
The strength of our analysis includes the use of data on dietary sodium intake based on measurements of multiple non-consecutive 24-h urines to minimize the potential for systematic bias and random error in sodium intake, and the careful assessment and a-priori exclusion of people at risk of CVD to minimize the potential for reverse causality. Our analysis also has a number of limitations. First, spot urine was not collected in TOHP and we used sodium concentration from 24-h urine instead. However, a key assumption in using spot urine to estimate sodium intake is that the ratio of spot urinary sodium-to-creatinine concentration is equivalent to that in 24-h urine.21  Indeed, in our analysis, the over- and under-estimation of sodium intake based on the Kawasaki formula with 24-h urine ADDIN EN.CITE 18 is similar to that found in studies with fasting morning spot urine. ADDIN EN.CITE 34 Second, the sample size was small with limited statistical power to test the relationship between sodium intake and mortality at the highest and lowest sodium levels. This could be one of the reasons for the statistically non-significant result for deviation from linearity, but significant linear association, when the curve appeared J-shaped. Third, no urine collection was made during follow-up and baseline sodium measurement does not reflect long-term intake. This is likely to have resulted in an under-estimation of the strength of the association between sodium intake and mortality, as demonstrated by a recent study with use of long-term multi-year 24-h urine collections.43 
Perspectives 
By comparing various estimates of sodium intake with the gold standard method of careful collections of multiple non-consecutive 24-h urines over a period of 18 months to 4 years, our analysis demonstrates that none of the three commonly used formulas can be used to estimate individuals’ sodium intake accurately. It is thus inappropriate to associate unreliable and biased estimations of sodium intake with mortality, particularly because the formulas per se seem to be related to death, independent of sodium intake. Paradoxical J-shaped findings reported in some cohort studies, ADDIN EN.CITE 12, 44 which use biased estimates of sodium intake from formulas with urinary sodium concentration, should not be used to refute the totality of evidence for the beneficial effects of population-wide reduction in sodium intake.26, 45
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Novelty and Significance
What Is New
	To our knowledge, our study is the first to have compared estimations of sodium intake by three commonly used formulas to accurately measured sodium intake by multiple non-consecutive 24-h urine collections in relation to mortality. 
	All estimated sodium intakes were systematically biased and altered the sodium-mortality relationship.
	An additional analysis keeping sodium concentration constant further confirmed the independent role of the formulas per se on the biased estimation of sodium intake and its association with deaths. 
What Is Relevant
	Some cohort studies using spot urine to estimate sodium intake by formulas reported a J-shaped association with mortality, with both lower and higher sodium intake being related to an increased risk. This caused controversay, casting doubt on the current public health recommendations of sodium reduction.
	Our study demonstrates that the paradoxical J-shaped findings are, at least partially, attributable to biased estimation of sodium intake using the formulas.  
Summary
Accurately measured sodium intake through mutiple non-consecutive 24-h urine collections showed a positive linear relationship with mortality down to a sodium level of 1,200 mg/d (3 g/d salt). Inaccurate estimations of sodium intake from spot urine by formulas altered this relationship. It is therefore vital to accurately assess an individual’s sodium intake in studies of health outcomes.



Figure legends 
Figure 1. Bland-Altman plot comparing estimated 24-h urinary sodium excretion with measured values during the trial periods. Na: 24-h urinary sodium excretion. Avg: Average.
Figure 2. Spline plots for the association between average estimates of 24-h urinary sodium excretion and all-cause mortality adjusted for age, sex, race/ethnicity, clinic, treatment assignment, education status, baseline weight, alcohol use, smoking, exercise, and family history of cardiovascular disease. Rug plot indicates distribution of sodium excretion. 4a: P (Linear)=0.029; P (Nonlinear)=0.87. 4b: P (Linear)=0.006; P (Nonlinear)=0.26. 4c: P (Linear)=0.13; P (Nonlinear)=0.083. 4d: P (Linear)=0.010; P (Nonlinear)=0.56.
Figure 3. Spline plots for the association between estimated 24-h urinary sodium excretion with constant sodium concentration and all-cause mortality adjusted for age, sex, race/ethnicity, clinic, treatment assignment, education status, baseline weight, alcohol use, smoking, exercise, and family history of cardiovascular disease. Avg: Average. 5a: P (Linear)=0.83; P (Nonlinear)=0.42. 5b: P (Linear)=0.82; P (Nonlinear)=0.64. 5c: P (Linear)=0.69; P (Nonlinear)=0.0048. 5d: P (Linear)=0.70; P (Nonlinear)=0.41. 5e: P (Linear)=0.73; P (Nonlinear)=0.64. 5f: P (Linear)=0.93; P (Nonlinear)=0.26.






Table 1. Total mortality in the TOHP cohorts post-trial follow-up by categories of measured 24-h urinary sodium excretion among individuals not in a sodium reduction intervention 
Variable	Measured Sodium Excretion (mg/24-h)	p Trend	Hazard ratios per 1,000 mg/24-h	p Value
	<2,300	2,300 to <3,600	3,600 to <4,800	≥4,800			
Average measured  24-h urinary sodium
Deaths/total (%)	23/312 (7.4)	105/1182 (8.9)	93/979 (9.5)	51/538 (9.5)			
Hazard ratios (95% CI)	0.73 (0.45-1.20)	0.94 (0.70-1.26)	1 (Reference)	1.09 (0.76-1.55)	0.204	1.12 (1.01-1.25)	0.032
First measured 24-h urinary sodium
Deaths/total (%)	44/440 (10.0)	71/811 (8.8)	57/693 (8.2)	68/716 (9.5)			
Hazard ratios (95% CI)	1.23 (0.81-1.86)	1.15 (0.80-1.64)	1 (Reference)	1.20 (0.84-1.73)	0.850	0.99 (0.91-1.06)	0.703
From Cox proportional hazards regression models stratified by trial phase and adjusted for age, sex, race/ethnicity, clinic, treatment assignment, education status, baseline weight, alcohol use, smoking, exercise, and family history of cardiovascular disease.
CI: confidence interval; TOHP: Trials of Hypertension Prevention.
Table 2. Total mortality in the TOHP cohorts post-trial follow-up by categories of estimated 24-h urinary sodium excretion using the Kawasaki, Tanaka and INTERSALT formulas among individuals not in a sodium reduction intervention 
Variable	Estimated sodium excretion (mg/24-h)	p Trend	Hazard ratios per 1,000 mg/24-h	p Value
	<3,600	3,600 to <4,800	4,800 to <6,000	≥6,000			
Estimated with Kawasaki formula
Average estimated 24-h urinary sodium
Deaths/total (%)	8/89 (9.0)	85/1100 (7.7)	132/1418 (9.3)	47/403 (11.7)			
Hazard ratios (95% CI)	1.26 (0.60-2.65)	1 (Reference)	1.39 (1.01-1.92)	1.83 (1.17-2.85)	0.015	1.28 (1.06-1.55)	0.010
Average estimated 24-h urinary sodium with constant sodium concentration
Deaths/total (%)	16/137(11.7)	73/972(7.5)	120/1216 (9.9)	63/685 (9.2)			
Hazard ratios (95% CI)	1.97(1.11-3.51)	1 (Reference)	1.18 (0.86-1.60)	1.06 (0.74-1.53)	0.640	1.01 (0.90-1.14)	0.820
First estimated 24-h urinary sodium
Deaths/total (%)	19/229 (8.3)	77/903 (8.5)	104/1130 (9.2)	46/478 (9.6)			
Hazard ratios (95% CI)	0.89 (0.53-1.48)	1 (Reference)	1.03 (0.75-1.41)	1.13 (0.75-1.70)	0.422	1.09 (0.95-1.25)	0.227
First estimated 24-h urinary sodium with constant sodium concentration
Deaths/total (%)	20/225 (8.9)	76/1013 (7.5)	98/904(10.8)	53/614 (8.6)			
Hazard ratios (95% CI)	1.52(0.89-2.58)	1 (Reference)	1.44 (1.06-1.97)	1.08(0.75-1.56)	0.932	0.98 (0.88-1.08)	0.671
	<3,600	3,600 to <4,800	≥4,800			
Estimated with Tanaka formula
Average estimated 24-h urinary sodium
Deaths/total (%)	64/810 (7.9)	192/2097 (9.2)	16/103 (15.5)			
Hazard ratios (95% CI)	0.78 (0.57-1.07)	1 (Reference)	2.05 (1.18-3.55)	0.015	1.50 (1.10-2.06)	0.011
Average estimated 24-h urinary sodium with constant sodium concentration
Deaths/total (%)	70/861(8.1)	164/1803(9.1)	38/346 (11.0)			
Hazard ratios (95% CI)	0.99 (0.74-1.34)	1 (Reference)	1.07 (0.74-1.53)	0.792	1.03(0.84-1.25)	0.805
First estimated 24-h urinary sodium
Deaths/total (%)	73/903 (8.1)	150/1661 (9.0)	23/176 (13.1)			
Hazard ratios (95% CI)	0.86 (0.64-1.16)	1 (Reference)	1.67 (1.05-2.65)	0.074	1.14 (0.91-1.44)	0.254
First estimated 24-h urinary sodium with constant sodium concentration
Deaths/total (%)	79/1062 (7.4)	137/1352 (10.1)	31/342(9.1)			
Hazard ratios (95% CI)	0.76 (0.57-1.02)	1 (Reference)	0.82 (0.55-1.23)	0.455	0.97 (0.82-1.15)	0.710
	<3,600	3,600 to <4,800	≥4,800			
Estimated with INTERSALT formula 
Average estimated 24-h urinary sodium
Deaths/total (%)	112/1367 (8.2)	141/1527 (9.2)	19/116 (16.4)			
Hazard ratios (95% CI)	0.94 (0.64-1.37)	1 (Reference)	1.84 (1.09-3.10)	0.333	1.29 (0.91-1.82)	0.161
Average estimated 24-h urinary sodium with constant sodium concentration
Deaths/total (%)	103/1366(7.5)	163/1605 (10.2)	6/39 (15.4)			
Hazard ratios (95% CI)	0.82 (0.54-1.23)	1 (Reference)	1.61(0.68-3.79)	0.435	1.11 (0.73-1.71)	0.621
First estimated 24-h urinary sodium
Deaths/total (%)	107/1244 (8.6)	119/1329 (9.0)	20/167 (12.0)			
Hazard ratios (95% CI)	1.15 (0.80-1.65)	1 (Reference)	1.20 (0.72-1.99)	0.876	1.07 (0.80-1.43)	0.642
First estimated 24-h urinary sodium with constant sodium concentration
Deaths/total (%)	105/1328(7.9)	137/1387 (9.9)	5/41(12.2)			
Hazard ratios (95% CI)	1.05 (0.72-1.51)	1 (Reference)	1.41(0.56-3.58)	0.844	1.00 (0.69-1.45)	0.996
From Cox proportional hazards regression models stratified by trial phase and adjusted for age, sex, race/ethnicity, clinic, treatment assignment, education status, baseline weight, alcohol use, smoking, exercise, and family history of cardiovascular disease.
CI: confidence interval; TOHP: Trials of Hypertension Prevention.
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